With more cha-ching, will PDUFA V satisfy on the ba-bling?
This article was originally published in Scrip
Executive Summary
The smooth sailing the Prescription Drug User Fee Act (PDUFA) reauthorization process experienced this past year – with the legislation getting through Congress with rare bipartisan support and little opposition in record time – does not necessarily mean there will be calm waters ahead for the US FDA, which must now follow through on the negotiated commitments it made, albeit with a few dollars more in its pocket and some added authorities and flexibility.
You may also be interested in...
AMR Roundtable: The Push And Pull Of Antimicrobial Development Incentives (Part 1)
The Pink Sheet spoke with CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about what's needed to boost antimicrobial drug development, including "push" and "pull" incentives for drug makers.
AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed
Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.